J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson cites the 2005 switch to the ASP-plus 6% reimbursement model among its reasons for optimism despite Procrit’s recent performance. Aranesp is gaining on J&J brand; Procrit market share slipped to 61% in second quarter.
You may also be interested in...
Price Competition To Procrit Is Beginning To Stabilize, J&J Says
Recent price increases for both Procrit and Amgen’s Aranesp indicate the discount war may be over for now, J&J says. The company remains positive about the impact of the 2005 changes to Medicare Part B drug reimbursement on Procrit’s positioning within the EPO market.
Price Competition To Procrit Is Beginning To Stabilize, J&J Says
Recent price increases for both Procrit and Amgen’s Aranesp indicate the discount war may be over for now, J&J says. The company remains positive about the impact of the 2005 changes to Medicare Part B drug reimbursement on Procrit’s positioning within the EPO market.
Future Aranesp Discounts Would Respond To Procrit Price Changes, Amgen Says
First quarter Aranesp pricing adjustments were Amgen’s answer to J&J’s new Procrit clinic contracts. Since the February price changes, Aranesp market share has grown five points, Amgen says.